Using 3D bioprinting for personalized treatment of pancreatic cancer
Exploring the Application of 3D Bioprinting Technology in Constructing Preclinical Models of Pancreatic Cancer for Drug Sensitivity Testing and Its Significance in Personalized Treatment
This study is testing if 3D printing can help create personalized treatment models for people with pancreatic cancer to find the best drugs for their specific tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 2 sites (Beijing, Beijing and 1 other locations) |
| Trial ID | NCT05955092 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the application of 3D bioprinting technology in creating personalized treatment models for pancreatic ductal adenocarcinoma. It will collect tumor tissue from participants to extract primary tumor cells, which will then be used to establish in vitro preclinical models. These models will be utilized for drug sensitivity testing to evaluate the effectiveness of potential treatments tailored to individual patients. The study seeks to determine the feasibility of using 3D bioprinting in the context of pancreatic cancer treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been diagnosed with pancreatic ductal adenocarcinoma.
Not a fit: Patients with a history of other malignancies or serious medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for patients with pancreatic cancer.
How similar studies have performed: While the application of 3D bioprinting in cancer treatment is a novel approach, similar studies have shown promise in other types of cancers, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * More than 18 years old * Diagnosed as colorectal cancer with or without liver metastases before * Pathologically proven colorectal cancer after surgery Exclusion Criteria: * History of other malignancies or serious medical conditions * Inability to provide independent informed consent
Where this trial is running
Beijing, Beijing and 1 other locations
- China-Japan Friendship Hospital — Beijing, Beijing, China (Recruiting)
- Peking Union Medical College Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Yilei Mao
- Email: pumch-liver@hotmail.com
- Phone: 8600-010-69156042
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.